Latest Breaking News On - Promising innovative medicine - Page 1 : comparemela.com

Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations

Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations New real-world evidence shows Beyfortus substantially reduced RSV lower respiratory tract.

United kingdomFrance generalUnited statesComunidad autonoma de aragonSandrine guendoulFederico martinon torresThomas kudsk larsenSally bainEvan berlandNicolas obristTarik elgoutniFelix lauscherCorentine driancourtNathalie phamThomas triompheUs centers for disease

Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U S for the Treatment of Duchenne Muscular Dystrophy (DMD)

Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U S for the Treatment of Duchenne Muscular Dystrophy (DMD)
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomRichardj dalyLambert eatonLife science allianceCatalyst pharmaceuticals incLicensor santhera pharmaceuticalsProperties in maintaining efficacyPatient assistance programExchange commissionDrug administrationCatalyst pharmaceuticalsHealth canadaNovel alternative corticosteroidDemonstrated propertiesMaintaining efficacy

Catalyst Pharmaceuticals Announces AGAMREE® Now

Catalyst Pharmaceuticals Announces AGAMREE® Now
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesRichardj dalyLambert eatonCatalyst pharmaceuticals incLife science alliancePatient assistance programExchange commissionLicensor santhera pharmaceuticalsProperties in maintaining efficacyCatalyst pharmaceuticalsDrug administrationHealth canadaNovel alternative corticosteroidDemonstrated propertiesMaintaining efficacy

KalVista Pharmaceuticals, Inc : KalVista Pharmaceuticals Awarded UK Promising Innovative Medicine (PIM) Designation for Sebetralstat

KalVista Pharmaceuticals, Inc : KalVista Pharmaceuticals Awarded UK Promising Innovative Medicine (PIM) Designation for Sebetralstat
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesStefan klotterBen palleikoBryan bakerJarrod aldomEuropean medicines agencyUnited kingdom health technology agenciesRegulatory agencyAmerican academy of allergyKalvista pharmaceuticals incNational health serviceExchange commissionCorporate communicationsMarketing authorizationVista pharmaceuticals

KalVista Pharmaceuticals (KALV) Grnated UK Promising Innovative Medicine (PIM) Designation for Sebetralstat

KalVista Pharmaceuticals (KALV) Grnated UK Promising Innovative Medicine (PIM) Designation for Sebetralstat
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesBen palleikoRegulatory agencyUnited kingdom health technology agenciesAmerican academy of allergyNational health serviceKalvista pharmaceuticals incKalvista pharmaceuticalsUnited kingdom medicinesPromising innovative medicineEarly accessMedicines schemeExpanded accessChief executive officerHealth technology